Prospects for use of interleukin-12 as a mucosal adjuvant for vaccination of humans to protect against respiratory pneumococcal infection

Vaccine

Volumn 26, Issue 38, 2008, Pages 4893-4903

  Wright, A K A ^a,d   Briles, D E ^b   Metzger, D W ^c   Gordon, S B ^d  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b University of Alabama at Birmingham   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

Lung; Mucosal vaccine; Streptococcus pneumoniae

Indexed keywords

ALPHA2B INTERFERON; CYTOKINE RECEPTOR; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INDOMETACIN; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 27; PARACETAMOL; PNEUMOCOCCUS VACCINE; RECOMBINANT INTERLEUKIN 12; RITUXIMAB; TRASTUZUMAB;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTHRALGIA; CAPILLARY LEAK SYNDROME; CHILL; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG EFFICACY; DYSPNEA; ERYTHEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HEADACHE; HEART ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INJECTION SITE REACTION; INSOMNIA; LETHARGY; LEUKOPENIA; LYMPHOCYTOPENIA; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PANIC; PLEURA EFFUSION; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT MUCOSA; REVIEW; RHINITIS; SIDE EFFECT; SKIN INDURATION; STOMATITIS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; STROKE; SYNCOPE; T LYMPHOCYTE SUBPOPULATION; THORAX PAIN; THROMBOCYTOPENIA; VACCINATION; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; IMMUNITY, MUCOSAL; INTERLEUKIN-12; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RESPIRATORY TRACT INFECTIONS;

EID: 50049109145     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.06.058     Document Type: Review

References (120)

1. Boyton R.J., and Openshaw P.J. Pulmonary defences to acute respiratory infection. Br Med Bull 61 (2002) 1-12
2. Holmgren J., and Czerkinsky C. Mucosal immunity and vaccines. Nat Med 11 4 Suppl. (April) (2005) S45-S53
3. Pashine A., Valiante N.M., and Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 11 4 Suppl. (April) (2005) S63-S68
4. Hausdorff W.P., Bryant J., Kloek C., Paradiso P.R., and Siber G.R. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis 30 1 (January) (2000) 122-140
5. Weber J.R. Pathogenesis of pneumococcal meningitis. In: Tuomanen E.I., Mitchell T.J., Morrison D.A., and Spratt B.G. (Eds). The pneumococcus (2004), ASM Press, Washington 238-280
6. Petersen I., Johnson A.M., Islam A., Duckworth G., Livermore D.M., and Hayward A.C. Protective effect of antibiotics against serious complications of common respiratory tract infections: retrospective cohort study with the UK General Practice Research Database. BMJ 335 7627 (November 10) (2007) 982
7. Gupta R, Limb E. The burden of lung disease: a statistics report from the British thoracic society. British Thoracic Society; June 2006.
8. Levine O.S., O'Brien K.L., Knoll M., Adegbola R.A., Black S., Cherian T., et al. Pneumococcal vaccination in developing countries. Lancet 367 9526 (January 10) (2006) 1880-1882
9. Berkley J.A., Lowe B.S., Mwangi I., Williams T., Bauni E., Mwarumba S., et al. Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med 352 1 (January 6) (2005) 39-47
10. Gordon S.B., Chaponda M., Walsh A.L., Whitty C.J., Gordon M.A., Machili C.E., et al. Pneumococcal disease in HIV-infected Malawian adults: acute mortality and long-term survival. AIDS 16 10 (July 5) (2002) 1409-1417
11. Sinha A., Levine O., Knoll M.D., Muhib F., and Lieu T.A. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 369 9559 (February 3) (2007) 389-396
12. Gordon S.B., Kanyanda S., Walsh A.L., Goddard K., Chaponda M., Atkinson V., et al. Poor potential coverage for 7-valent pneumococcal conjugate vaccine, Malawi. Emerg Infect Dis 9 6 (June) (2003) 747-749
13. Bogaert D., De Groot R., and Hermans P.W. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 4 3 (March) (2004) 144-154
14. Buchanan R.M., Briles D.E., Arulanandam B.P., Westerink M.A., Raeder R.H., and Metzger D.W. IL-12-mediated increases in protection elicited by pneumococcal and meningococcal conjugate vaccines. Vaccine 19 15-16 (February 28) (2001) 2020-2028
15. Aguilar J.C., and Rodriguez E.G. Vaccine adjuvants revisited. Vaccine 25 19 (May 10) (2007) 3752-3762
16. Freytag L.C., and Clements J.D. Mucosal adjuvants. Vaccine 23 15 (March 7) (2005) 1804-1813
17. Chabalgoity J.A., Baz A., Rial A., and Grille S. The relevance of cytokines for development of protective immunity and rational design of vaccines. Cytokine Growth Factor Rev 18 1-2 (February-April) (2007) 195-207
18. Kobayashi M., Fitz L., Ryan M., Hewick R.M., Clark S.C., Chan S., et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170 3 (September 1) (1989) 827-845
19. Stern A.S., Podlaski F.J., Hulmes J.D., Pan Y.C., Quinn P.M., Wolitzky A.G., et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 87 17 (September) (1990) 6808-6812
20. Gubler U., Chua A.O., Schoenhaut D.S., Dwyer C.M., McComas W., Motyka R., et al. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 88 10 (May 15) (1991) 4143-4147
21. Afonso L.C., Scharton T.M., Vieira L.Q., Wysocka M., Trinchieri G., and Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263 5144 (January 14) (1994) 235-237
22. Arulanandam B.P., O'Toole M., and Metzger D.W. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis 180 4 (October) (1999) 940-949
23. Albu D.I., Jones-Trower A., Woron A.M., Stellrecht K., Broder C.C., and Metzger D.W. Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins. J Virol 77 10 (May) (2003) 5589-5597
24. Bradney C.P., Sempowski G.D., Liao H.X., Haynes B.F., and Staats H.F. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J Virol 76 2 (January) (2002) 517-524
25. Lee S., Gierynska M., Eo S.K., Kuklin N., and Rouse B.T. Influence of DNA encoding cytokines on systemic and mucosal immunity following genetic vaccination against herpes simplex virus. Microbes Infect 5 7 (June) (2003) 571-578
26. Sun K., Salmon S.L., Lotz S.A., and Metzger D.W. Interleukin-12 promotes gamma interferon-dependent neutrophil recruitment in the lung and improves protection against respiratory Streptococcus pneumoniae infection. Infect Immun 75 3 (March) (2007) 1196-1202
27. Arulanandam B.P., Lynch J.M., Briles D.E., Hollingshead S., and Metzger D.W. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun 69 11 (November) (2001) 6718-6724
28. Lynch J.M., Briles D.E., and Metzger D.W. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun 71 8 (August) (2003) 4780-4788
29. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3 2 (February) (2003) 133-146
30. Trinchieri G., Pflanz S., and Kastelein R.A. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 19 5 (November) (2003) 641-644
31. Hunter C.A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 5 7 (July) (2005) 521-531
32. Kastelein R.A., Hunter C.A., and Cua D.J. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 25 (2007) 221-242
33. Presky D.H., Yang H., Minetti L.J., Chua A.O., Nabavi N., Wu C.Y., et al. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci USA 93 24 (November 26) (1996) 14002-14007
34. Yamasaki H., Ando M., Brazer W., Center D.M., and Cruikshank W.W. Polarized type 1 cytokine profile in bronchoalveolar lavage T cells of patients with hypersensitivity pneumonitis. J Immunol 163 6 (September 15) (1999) 3516-3523
35. Vogel L.A., Showe L.C., Lester T.L., McNutt R.M., Van Cleave V.H., and Metzger D.W. Direct binding of IL-12 to human and murine B lymphocytes. Int Immunol 8 12 (December) (1996) 1955-1962
36. Bastos K.R., Marinho C.R., Barboza R., Russo M., Alvarez J.M., and D'Imperio Lima M.R. What kind of message does IL-12/IL-23 bring to macrophages and dendritic cells?. Microbes Infect 6 6 (May) (2004) 630-636
37. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13 5 (November) (2000) 715-725
38. Parham C., Chirica M., Timans J., Vaisberg E., Travis M., Cheung J., et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 168 11 (June 1) (2002) 5699-5708
39. Aggarwal S., Ghilardi N., Xie M.H., de Sauvage F.J., and Gurney A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278 3 (January 17) (2003) 1910-1914
40. Fitzgerald D.C., Zhang G.X., El-Behi M., Fonseca-Kelly Z., Li H., Yu S., et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol 8 12 (December) (2007) 1372-1379
41. McGeachy M.J., Bak-Jensen K.S., Chen Y., Tato C.M., Blumenschein W., McClanahan T., et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 8 12 (December) (2007) 1390-1397
42. Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., and Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8 9 (September) (2007) 942-949
43. Wilson N.J., Boniface K., Chan J.R., McKenzie B.S., Blumenschein W.M., Mattson J.D., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8 9 (September) (2007) 950-957
44. Lucas S., Ghilardi N., Li J., and de Sauvage F.J. IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms. Proc Natl Acad Sci USA 100 25 (December 9) (2003) 15047-15052
45. Pflanz S., Timans J.C., Cheung J., Rosales R., Kanzler H., Gilbert J., et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 16 6 (June) (2002) 779-790
46. Goriely S., Neurath M.F., and Goldman M. How microorganisms tip the balance between interleukin-12 family members. Nat Rev Immunol 8 1 (January) (2008) 81-86
47. Jelinek D.F., and Braaten J.K. Role of IL-12 in human B lymphocyte proliferation and differentiation. J Immunol 154 4 (February 15) (1995) 1606-1613
48. Yoshimoto T., Okamura H., Tagawa Y.I., Iwakura Y., and Nakanishi K. Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-gamma production from activated B cells. Proc Natl Acad Sci USA 94 8 (April 15) (1997) 3948-3953
49. Skok J., Poudrier J., and Gray D. Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: a feedback regulation of Th1 development. J Immunol 163 8 (October 15) (1999) 4284-4291
50. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 13 2 (February) (2007) 139-145
51. Yao Z., Painter S.L., Fanslow W.C., Ulrich D., Macduff B.M., Spriggs M.K., et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 155 12 (December 15) (1995) 5483-5486
52. Moseley T.A., Haudenschild D.R., Rose L., and Reddi A.H. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 14 2 (April) (2003) 155-174
53. Liang S.C., Tan X.Y., Luxenberg D.P., Karim R., Dunussi-Joannopoulos K., Collins M., et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203 10 (October 2) (2006) 2271-2279
54. Yao Z., Spriggs M.K., Derry J.M., Strockbine L., Park L.S., VandenBos T., et al. Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 9 11 (November) (1997) 794-800
55. McAllister F., Henry A., Kreindler J.L., Dubin P.J., Ulrich L., Steele C., et al. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis. J Immunol 175 1 (July 1) (2005) 404-412
56. Jovanovic D.V., Di Battista J.A., Martel-Pelletier J., Jolicoeur F.C., He Y., Zhang M., et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 160 7 (April 1) (1998) 3513-3521
57. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6 11 (November) (2005) 1133-1141
58. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 7 11 (November) (2007) 875-888
59. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6 11 (November) (2005) 1123-1132
60. Arulanandam B.P., and Metzger D.W. Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery. Vaccine 17 3 (January 21) (1999) 252-260
61. Arulanandam B.P., Van Cleave V.H., and Metzger D.W. IL-12 is a potent neonatal vaccine adjuvant. Eur J Immunol 29 1 (January) (1999) 256-264
62. Jankovic D., and Trinchieri G. IL-10 or not IL-10: that is the question. Nat Immunol 8 12 (December) (2007) 1281-1283
63. Bonhoeffer J., Kohl K., Chen R., Duclos P., Heijbel H., Heininger U., et al. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 21 34 (December 13) (2002) 298-302
64. Kohl K.S., Bonhoeffer J., Chen R., Duclos P., Heijbel H., Heininger U., et al. The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiol Drug Safe 12 4 (June) (2003) 335-340
65. Portielje J.E., Kruit W.H., Eerenberg A.J., Schuler M., Sparreboom A., Lamers C.H., et al. Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant. Cancer Immunol Immunother 54 1 (January) (2005) 37-43
66. Hamid O., Solomon J.C., Scotland R., Garcia M., Sian S., Ye W., et al. Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res 13 1 (January 1) (2007) 215-222
67. Cebon J., Jager E., Shackleton M.J., Gibbs P., Davis I.D., Hopkins W., et al. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun 3 (June 16) (2003) 7
68. Peterson A.C., Harlin H., and Gajewski T.F. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 21 12 (June 15) (2003) 2342-2348
69. Gajewski T.F., Fallarino F., Ashikari A., and Sherman M. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res 7 3 Suppl. (March) (2001) 895s-901s
70. Hedlund J., Langer B., Konradsen H.B., and Ortqvist A. Negligible adjuvant effect for antibody responses and frequent adverse events associated with IL-12 treatment in humans vaccinated with pneumococcal polysaccharide. Vaccine 20 1-2 (October 12) (2001) 164-169
71. Jacobson M.A., Sinclair E., Bredt B., Agrillo L., Black D., Epling C.L., et al. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. Vaccine 24 25 (June 19) (2006) 5311-5319
72. Paton J. New pneumococcal vaccines: basic science developments. In: Tuomanen E. (Ed). The pneumococcus (2004), ASM Press, Washington 427
73. Sabirov A., and Metzger D.W. Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media. Vaccine 24 27-28 (July 7) (2006) 5584-5592
74. Buchanan R.M., Arulanandam B.P., and Metzger D.W. IL-12 enhances antibody responses to T-independent polysaccharide vaccines in the absence of T and NK cells. J Immunol 161 10 (November 15) (1998) 5525-5533
75. Kadioglu A., and Andrew P.W. The innate immune response to pneumococcal lung infection: the untold story. Trends Immunol 25 3 (March) (2004) 143-149
76. Sun K., Johansen F.E., Eckmann L., and Metzger D.W. An important role for polymeric Ig receptor-mediated transport of IgA in protection against Streptococcus pneumoniae nasopharyngeal carriage. J Immunol 173 7 (October 1) (2004) 4576-4581
77. Basset A., Thompson C.M., Hollingshead S.K., Briles D.E., Ades E.W., Lipsitch M., et al. Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins. Infect Immun 75 11 (November) (2007) 5460-5464
78. Malley R., Trzcinski K., Srivastava A., Thompson C.M., Anderson P.W., and Lipsitch M. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci USA 102 13 (March 29) (2005) 4848-4853
79. van Rossum A.M., Lysenko E.S., and Weiser J.N. Host and bacterial factors contributing to the clearance of colonization by Streptococcus pneumoniae in a murine model. Infect Immun 73 11 (November) (2005) 7718-7726
80. Lauw F.N., Branger J., Florquin S., Speelman P., van Deventer S.J., Akira S., et al. IL-18 improves the early antimicrobial host response to pneumococcal pneumonia. J Immunol 168 1 (January 1) (2002) 372-378
81. Yoshimoto T., Takeda K., Tanaka T., Ohkusu K., Kashiwamura S., Okamura H., et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol 161 7 (October 1) (1998) 3400-3407
82. Haraguchi S., Day N.K., Nelson Jr. R.P., Emmanuel P., Duplantier J.E., Christodoulou C.S., et al. Interleukin 12 deficiency associated with recurrent infections. Proc Natl Acad Sci USA 95 22 (October 27) (1998) 13125-13129
83. Yamamoto N., Kawakami K., Kinjo Y., Miyagi K., Kinjo T., Uezu K., et al. Essential role for the p40 subunit of interleukin-12 in neutrophil-mediated early host defense against pulmonary infection with Streptococcus pneumoniae: involvement of interferon-gamma. Microbes Infect 6 14 (November) (2004) 1241-1249
84. Thipphawong J. Inhaled cytokines and cytokine antagonists. Adv Drug Deliv Rev 58 9-10 (October 31) (2006) 1089-1105
85. Moss R.B., Mayer-Hamblett N., Wagener J., Daines C., Hale K., Ahrens R., et al. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr Pulmonol 39 3 (March) (2005) 209-218
86. Huber V.C., Arulanandam B.P., Arnaboldi P.M., Elmore M.K., Sheehan C.E., Kallakury B.V., et al. Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int Immunopharmacol 3 6 (June) (2003) 801-809
87. Schulz H., Brand P., and Heyder J. Particle deposition in the respiratory tract. In: Gehr P., and Heyder J. (Eds). Particle-lung interactions (2000), Marcel Dekker, New York 229-277
88. Portielje J.E., Lamers C.H., Kruit W.H., Sparreboom A., Bolhuis R.L., Stoter G., et al. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. Clin Cancer Res 9 1 (January) (2003) 76-83
89. Mash B., Bheekie A., and Jones P.W. Inhaled vs. oral steroids for adults with chronic asthma. Cochrane Database Syst Rev 1 (2001) [CD002160]
90. Zhang Q., Bagrade L., Bernatoniene J., Clarke E., Paton J.C., Mitchell T.J., et al. Low CD4 T cell immunity to pneumolysin is associated with nasopharyngeal carriage of pneumococci in children. J Infect Dis 195 8 (April 15) (2007) 1194-1202
91. Svartengren M., and Svartengren K. Medicinal particles. In: Gehr P., and Heyder J. (Eds). Particle-lung interactions (2000), Marcel Dekker, New York 171-211
92. Portielje J.E., Kruit W.H., Schuler M., Beck J., Lamers C.H., Stoter G., et al. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res 5 12 (December) (1999) 3983-3989
93. Alatrash G., Hutson T.E., Molto L., Richmond A., Nemec C., Mekhail T., et al. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. J Clin Oncol 22 14 (July 15) (2004) 2891-2900
94. Motzer R.J., Rakhit A., Schwartz L.H., Olencki T., Malone T.M., Sandstrom K., et al. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 4 5 (May) (1998) 1183-1191
95. Rakhit A., Yeon M.M., Ferrante J., Fettner S., Nadeau R., Motzer R., et al. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice. Clin Pharmacol Ther 65 6 (June) (1999) 615-629
96. Ohno R., Yamaguchi Y., Toge T., Kinouchi T., Kotake T., Shibata M., et al. A dose-escalation and pharmacokinetic study of subcutaneously administered recombinant human interleukin 12 and its biological effects in Japanese patients with advanced malignancies. Clin Cancer Res 6 7 (July) (2000) 2661-2669
97. Bajetta E., Del Vecchio M., Mortarini R., Nadeau R., Rakhit A., Rimassa L., et al. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res 4 1 (January) (1998) 75-85
98. Ansell S.M., Witzig T.E., Kurtin P.J., Sloan J.A., Jelinek D.F., Howell K.G., et al. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood 99 1 (January 1) (2002) 67-74
99. Duvic M., Sherman M.L., Wood G.S., Kuzel T.M., Olsen E., Foss F., et al. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. J Am Acad Dermatol 55 5 (November) (2006) 807-813
100. Rook A.H., Wood G.S., Yoo E.K., Elenitsas R., Kao D.M., Sherman M.L., et al. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 94 3 (August 1) (1999) 902-908
101. Rook A.H., Zaki M.H., Wysocka M., Wood G.S., Duvic M., Showe L.C., et al. The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann NY Acad Sci 941 (September) (2001) 177-184
102. Jacobson M.A., Hardy D., Connick E., Watson J., and DeBruin M. Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4 cells/microL. J Infect Dis 182 4 (October) (2000) 1070-1076
103. Jacobson M.A., Spritzler J., Landay A., Chan E., Katzenstein D., Schock B., et al. A phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection. AIDS 16 8 (May 24) (2002) 1147-1154
104. Little R.F., Pluda J.M., Wyvill K.M., Rodriguez-Chavez I.R., Tosato G., Catanzaro A.T., et al. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood 107 12 (June 15) (2006) 4650-4657
105. Carreno V., Zeuzem S., Hopf U., Marcellin P., Cooksley W.G., Fevery J., et al. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. J Hepatol 32 2 (February) (2000) 317-324
106. Zeuzem S., and Carreno V. Interleukin-12 in the treatment of chronic hepatitis B and C. Antiviral Res 52 2 (November) (2001) 181-188
107. O'Brien C.B., Moonka D.K., Henzel B.S., Caufield M., and DeBruin M.F. A pilot trial of recombinant interleukin-12 in patients with chronic hepatitis C who previously failed treatment with interferon-alpha. Am J Gastroenterol 96 8 (August) (2001) 2473-2479
108. Pockros P.J., Patel K., O'Brien C., Tong M., Smith C., Rustgi V., et al. A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients non-responsive to previous therapy. Hepatology 37 6 (June) (2003) 1368-1374
109. Zeuzem S., Hopf U., Carreno V., Diago M., Shiffman M., Grune S., et al. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C. Hepatology 29 4 (April) (1999) 1280-1287
110. Bryan S.A., O'Connor B.J., Matti S., Leckie M.J., Kanabar V., Khan J., et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356 9248 (December 23-30) (2000) 2149-2153
111. Wadler S., Levy D., Frederickson H.L., Falkson C.I., Wang Y., Weller E., et al. A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. Gynecol Oncol 92 3 (March) (2004) 957-964
112. Hurteau J.A., Blessing J.A., DeCesare S.L., and Creasman W.T. Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 82 1 (July) (2001) 7-10
113. Younes A., Pro B., Robertson M.J., Flinn I.W., Romaguera J.E., Hagemeister F., et al. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res 10 16 (August 15) (2004) 5432-5438
114. Robertson M.J., Pelloso D., Abonour R., Hromas R.A., Nelson Jr. R.P., Wood L., et al. Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies. Clin Cancer Res 8 11 (November) (2002) 3383-3393
115. Parihar R., Nadella P., Lewis A., Jensen R., De Hoff C., Dierksheide J.E., et al. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res 10 15 (August 1) (2004) 5027-5037
116. Atkins M.B., Robertson M.J., Gordon M., Lotze M.T., DeCoste M., DuBois J.S., et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3 3 (March) (1997) 409-417
117. Leonard J.P., Sherman M.L., Fisher G.L., Buchanan L.J., Larsen G., Atkins M.B., et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90 7 (October 1) (1997) 2541-2548
118. Gollob J.A., Mier J.W., Veenstra K., McDermott D.F., Clancy D., Clancy M., et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 6 5 (May) (2000) 1678-1692
119. Eisenbeis C.F., Lesinski G.B., Anghelina M., Parihar R., Valentino D., Liu J., et al. Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12. J Clin Oncol 23 34 (December 1) (2005) 8835-8844
120. Gollob J.A., Veenstra K.G., Parker R.A., Mier J.W., McDermott D.F., Clancy D., et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 21 13 (July 1) (2003) 2564-2573